>
-Midland identifie plusieurs projets prometteurs pour son important potentiel en lithium dans son vaste portefeuille de propriétés à la Baie-James-DEUTZ AG: DEUTZ enters into cooperation with Daimler Truck to develop and market medium- and heavy-duty engines-Best's Market Segment Report: Clouds on the Horizon For 2023, But Trade Credit Insurers Are in a Good Place-Crédit Agricole Loire Haute-Loire : Communiqué financier 2022-Consumer Optimism Remains Strong Despite Economic Headwinds, Per 2022 Holiday Spending Report From ACI Worldwide-Philips sees some improvement in Q4 2022 and takes firm actions to address operational challenges in an uncertain environment-Alipay and AlipayHK Cross-Border Transactions Rebound During Chinese New Year as Travels Resume- EnCap and Double Eagle Announce Equity Upsize to $2.3 Billion in Commitments and Establishment of RBL Facility-Top 10 ciudades más caras para vivir del mundo-Online Shopping Market Share, Growth [2023] | Global Online Shopping Market Size is set to Develop at a Noteworthy Speed in the Forthcoming Years till 2028-Subscriber Data Management Market 2023 | Forecast Report, 2028 | Subscriber Data Management Market Size to see Promising Growth Ahead, Latest Research study | Detailed Analysis by 106 Pages Research-Sandboxing Market Size, Share | Research Report, 2023 | Sandboxing Market Might Set a Superb Growth Development by Forecast 2023-2028 | Latest Detailed Analysis by 106 Pages Research-Biodegradable Packaging Market Share, Growth [2023] | Biodegradable Packaging Market Size Changing Rapidly Because of Financial Development and Arising Valuable Opportunities by Forecast 2023-2028 | 113 Pages Research-Doll Market 2023 (New Report) Analysis By Advanced Technology, Market Size-Share, Industry Dynamic (Drivers, Trends, Challenges, Restraints), Market Contribution, Top Companies Strategy, and Consumption Trend till 2028-Plastic Pallets Market 2023: Growing Demand Analysis by Companies Strategy, Recent Developments, Business Segments, Product and Services, Industry Position, Revenue and Forecast till 2028 Research-Diaper Market Size & Forecast 2023-2028 By Global Industry Trends, Regional Overview, Share Estimation, Emerging Technologies, Majoe Key Players, Revenue Expectation, and Business Share | Industry Research Biz-Organic Meat Market 2023 Size Growing at a CAGR of 7.5% to Reach US$ 38220 Million during 2023-2028 | Covid-19 Impact Analysis by Sales Revenue, Future Demands, Growth Factors, Emerging Trends, & Competitive Landscape-Luxury Bag Market Size [2023] By Emerging Trends, Industry Share, Growth Strategy, Developing Technologies, Market Potential, Key Players, Regional Overview, Revenue and Covid-19 Impact Analysis till 2028-Night Vision Devices Market Size & Forecast [2023-2028] By Global Industry Trends, Key Players, Development History, Regional Overview, Share Estimation, Revenue, and Business Prospect, Says Industry Research Biz-Coffee Pod Market Size 2023 (New Report) By Emerging Demand, Vendor Landscape, Growth Rate, Industry Contribution & Insight, Key Challenges, Recent Developments, Type & Application, Revenue and Forecast to 2028 Research

Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results

DUBLIN, Ohio–()–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2022.

Second Quarter 2022 Highlights and Subsequent Events

  • Continued enrollment into the Company’s NAV3-33 Phase 3 trial in rheumatoid arthritis (“RA”) titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis.” Enrollment is ongoing across the three currently opened sites.
  • Announced positive preliminary results from the Company’s ongoing NAV3-32 Phase 2b trial comparing Tc99m tilmanocept imaging to histopathology of joints of patients with active RA. Two non-overlapping classes that align with the fibroid and non-fibroid histological pathotypes were identified, supporting the hypothesis that these classes can be identified by Tc99m tilmanocept imaging.
  • Received $800,000 from a strategic partner as reimbursement for certain manufacturing and research and development expenses.
  • The Company’s abstract titled “TAM Targeted Imaging Agents Binding CD206 and Selective Blocking of Off Target Liver Localization” was presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting on June 11, 2022 in Vancouver, British Columbia.
  • The Company’s abstract titled “CD206 Targeted Delivery of Bisphosphonate Payloads Alter Human Macrophage Phenotypes Towards M1-like” was presented at the Tumor Myeloid-Directed Therapies Summit on June 14, 2022 in Boston, MA.
  • Announced publication of a manuscript titled “Increased Macrophage Specific Arterial Inflammation Relates Uniquely to Non-calcified Plaque and Specific Immune Activation Pathways in People with HIV: A Targeted Molecular Imaging Approach,” based on work performed at the Massachusetts General Hospital (“MGH”) and Harvard Medical School, Boston MA, and sponsored by the Company. The research, appearing in The Journal of Infectious Diseases (PMID: 35856671), was led by Principal Investigator Steven Grinspoon, MD, Chief of the Metabolism Unit at MGH and Professor of Medicine at Harvard Medical School.
  • Announced publication of a manuscript titled “Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer,” based on work performed at the Crown Princess Mary Cancer Centre (“CPMCC”) at the University of Sydney, in Sydney, Australia. The research, appearing in the ANZ Journal of Surgery (PMID: 35848587), was led by Principal Investigator Dr. Muzib Abdul-Razak, MBBS, FRACS, FRCSE, MCh., of the Faculty of Medicine, Department of Surgical Oncology and Head and Neck Surgery in the CPMCC at the University of Sydney.
  • Received notification of issuance of patent from the USPTO for the application titled, “Compounds And Compositions For Treating Leishmaniasis And Methods Of Diagnosis And Treating Using Same” (Patent No. US 11,369,680 B2).
  • Filed a provisional patent application describing a new degradable linker for dexamethasone and paclitaxel containing Manocept therapeutic constructs. These constructs are being evaluated preclinically for effects on macrophages and in animal models of oncology and inflammatory indications.
  • Received a Decision of Grant for patent application in Japan for claims related to targeted delivery of a wide range of therapeutic payloads attached to Manocept platform-based constructs using a degradable hydrazone linker.
  • Closed on a $2.5 million bridge loan from the Company’s Vice Chair of the Board of Directors, John K. Scott, Jr.
  • Adopted a plan designed to protect the Company’s net operating loss and tax credit carryforwards.

Michael Rosol, Ph.D., Chief Medical Officer for Navidea, said, “The company continues to work diligently to advance the technology in key disease areas, with an emphasis on our RA program. The NAV3-33 Phase 3 and NAV3-32 Phase 2b trials continue to enroll. We are pleased with the preliminary positive results from the NAV3-32 study that thus far support our hypothesis that we can distinguish between fibroid and non-fibroid pathotypes of RA with a single scan.” Dr. Rosol continued, “Concurrent with all of this, we continue to make progress in our therapeutics pipeline, and we expect to keep advancing these towards the clinic.”

Financial Results

  • Total net revenues for the second quarter of 2022 were $57,000, compared to $261,000 for the same period in 2021. Total net revenues for the first half of 2022 were $57,000, compared to $385,000 for the same period in 2021. The decrease was primarily due to the 2021 partial recovery of debts previously written off in 2015, the 2021 receipt of reimbursement from Cardinal Health 414, LLC of certain research and development (“R&D”) costs, decreased grant revenue related to Small Business Innovation Research grants from the National Institutes of Health supporting Manocept development, and decreased license revenue from transitional sales of Tc99m tilmanocept in Europe.
  • Research and development expenses for the second quarter of 2022 were $1.7 million, compared to $1.5 million for the same period in 2021. R&D expenses for the first half of 2022 were $2.9 million, compared to $2.7 million for the same period in 2021. The increase was primarily due to increased employee compensation including incentive-based awards and increased recruiting fees, offset by decreases in drug project expenses and regulatory consulting expenses.
  • Selling, general and administrative (“SG&A”) expenses for the second quarter of 2022 were $1.3 million, compared to $1.4 million for the same period in 2021. SG&A expenses for the first half of 2022 were $3.1 million, compared to $3.7 million for the same period in 2021. Decreases in employee compensation including fringe benefits and incentive-based awards, travel, investor relations, general office expenses, facilities costs and franchise taxes were offset by increases in insurance, director fees, losses on the abandonment of certain intellectual property and legal and professional services.
  • Navidea’s net loss attributable to common stockholders for the second quarter of 2022 was $3.0 million, or $0.10 per share, compared to $2.7 million, or $0.09 per share, for the same period in 2021. Navidea’s net loss attributable to common stockholders for the first half of 2022 was $6.0 million, or $0.20 per share, compared to $5.6 million, or $0.20 per share, for the same period in 2021.
  • Navidea ended the second quarter of 2022 with $328,000 million in cash and cash equivalents.

The Company’s registration statement on Form S-1 (Registration No. 333-262691) relative to the Company’s current rights offering was declared effective by the Securities and Exchange Commission (“SEC”) on August 3, 2022. The prospectus relating to and describing the terms of the rights offering has been filed with the SEC as a part of the registration statement and is available on the SEC’s web site at http://www.sec.gov. Copies of the final prospectus for the rights offering may be obtained, when available, from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention Syndicate Department, email: syndicate@maximgrp.com or telephone (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

In light of the Company’s pending rights offering, the Company will host a second quarter earnings conference call and business update following the conclusion of the rights offering. The Company will issue a press release announcing the date and time of the earnings conference call.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.

Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.

NAVIDEA BIOPHARMACEUTICALS, INC.
 
CONDENSED CONSOLIDATED BALANCE SHEETS

June 30,

December 31,

2022

2021

(unaudited)
Assets:
Cash and cash equivalents

$

328,012

$

4,230,865

Other current assets

842,728

1,152,420

Non-current assets

1,332,965

1,261,548

Total assets

$

2,503,705

$

6,644,833

 
Liabilities and stockholders’ (deficit) equity:
Current liabilities

$

5,321,985

$

5,299,802

Deferred revenue, non-current

700,000

700,000

Note payable to related party, net of discount

720,305

Other liabilities

2,062

20,288

Total liabilities

6,744,352

6,020,090

Total stockholders’ deficit

(4,533,164

)

(106,556

)

Noncontrolling interest

292,517

731,299

Total Navidea stockholders’ (deficit) equity

(4,240,647

)

624,743

Total liabilities and stockholders’ (deficit) equity

$

2,503,705

$

6,644,833

 
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 

Three Months Ended

Six Months Ended

June 30,

June 30,

June 30,

June 30,

2022

2021

2022

2021

(unaudited)

(unaudited)

(unaudited)

(unaudited)

 
Revenue

$

57,526

$

261,046

$

57,526

$

384,783

Cost of revenue

473

473

Gross profit

57,053

261,046

57,053

384,783

Operating expenses:
Research and development

1,723,988

1,498,056

2,893,242

2,720,810

Selling, general and administrative

1,255,666

1,432,610

3,065,695

3,663,355

Total operating expenses

2,979,654

2,930,666

5,958,937

6,384,165

Loss from operations

(2,922,601

)

(2,669,620

)

(5,901,884

)

(5,999,382

)

Other income (expense):
Interest (expense) income, net

(83,584

)

1,266

(87,246

)

(1,609

)

Gain on extinguishment of debt

366,000

Other, net

6,726

(5,686

)

2,427

(5,941

)

Net loss

(2,999,459

)

(2,674,040

)

(5,986,703

)

(5,640,932

)

Loss attributable to noncontrolling interest

1

1

3

3

Net loss attributable to common stockholders

$

(2,999,458

)

$

(2,674,039

)

$

(5,986,700

)

$

(5,640,929

)

 
Loss attributable to common stockholders
per common share (basic and diluted)

$

(0.10

)

$

(0.09

)

$

(0.20

)

$

(0.20

)

Weighted average shares outstanding (basic and diluted)

30,268,858

29,117,832

30,238,471

28,531,660

Leave a Comment